

Attestation

As part of a research assignment of SwissMedtechSolutions, Gärtnerstraße 18, 8400 Winterthur, Switzerland, RECON Freiburg conducted a randomized, placebo controlled, double-blind documentation study whose aim was to replicate the effectiveness of the Biotransmitter XO in chronic and recurring pain.

The main outcomes of the study were as follows:

1. **The Biotransmitter XO's specific effect exceeded the unspecific effects (e.g. natural pain course, placebo effect) by more than 150 percent.**
2. **The Biotransmitter XO reduced pain intensity from moderate-strong to small (effect size: $d = 1.4$).**
3. **The Biotransmitter XO cut by half the time until pain noticeably decreased. The reduction was from 57 minutes to 25 minutes (55 per cent).**
4. **The Biotransmitter XO reduced the time pain lasted by over one hour (84 minutes).**
5. **The Biotransmitter XO improved overall wellbeing by 9 percent.**

Freiburg, 04/28/2014



Dr. Rainer Schneider